Sign in
Active, not recruitingNo phase

First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA)

Key facts

Who runs it
Nectero Medical, Inc.
Where
Australia, China, Colombia, Latvia, and New Zealand5 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
46 people enrolled
Started
24 Jun 2019
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Endovascular Aneurysm Stabilization Treatment (EAST)
Record updated
16 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Male or Female aged 18 years or older
  • Subject can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent and is willing to complete the follow-up according to the requirements of the protocol
  • Infrarenal non-aneurysmal neck ≥15mm in length
  • Aortic neck diameters ≤ 29mm
  • Infrarenal neck angulation ≤ 60°
  • Abdominal aneurysm from 3.5 cm to 5.0 cm
  • Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 10 cm
  • Patient iliac or femoral arteries access vessels' size and morphology allow endovascular access of 14F introducer sheaths and catheters
  • Subject has > one-year life expectancy
  • Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive
  • Subject is able and willing to comply with 1, 3, 6, 12, 24 and 36-month follow-up

Who cannot take part

  • Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm
  • Subject has had a myocardial infarction within six (6) months prior to enrollment
  • Subject has undergone other major surgery within the 30 days prior to enrollment
  • Known allergy to polyester or contrast material that cannot be pretreated
  • Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment
  • Subject has a mycotic or infected aneurysm
  • Subject has current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular disease
  • Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months
  • Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta
  • Subject has connective tissue disease (e.g., Marfan syndrome, Eaton syndrome, or Bessel's disease)
  • Subject has active systemic infection
  • Subject has dialysis dependent renal failure or baseline serum creatinine level >2.0mg/dl
  • Subjects with liver dysfunction: alanine transaminase (ALT) or aspartate transaminase (AST) is five times higher than the normal upper limit; serum total bilirubin (STB) is two times higher than the normal upper limit
  • Subject has an acutely ruptured or leaking or emergent aneurysm
  • Subject has a dissecting aneurysm
  • Subject has current vascular injury due to trauma
  • Subject's aneurysm is thoracic or suprarenal
  • Subject has thrombus, calcification, and/or plaque that may compromise delivery
  • Known contraindication to undergoing angiography or anticoagulation
  • Subject is participating in another research study
  • Women of childbearing potential who are pregnant, lactating, or planning to become pregnant during the course of the trial
  • Subjects who are not suitable for endovascular treatment, as judged by the investigator

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a first in human study to evaluate the safety and clinical utility of an investigational medical device called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.

The group in the trial

  • InterventionalTreatment being tested

    Use of the EAST System for the stabilization treatment of AAA. The device is delivered endovascularly and placed in the AAA sac to deliver the Stabilizer Infusion Solution.

    Treatment: Endovascular Aneurysm Stabilization Treatment (EAST)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Pilot Study to Evaluate the Safety and Clinical Utility of The Nectero EAST System for Stabilization of Abdominal Aortic Aneurysms
Record updated
16 December 2025